Drugs / MEDI-578
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01072591 | Feb → Sep 2010 | osteoarthritis, knee | AstraZeneca | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI-578 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01072591 ↗ |
| Action | Inhibit | “Beta-nerve growth factor inhibitor” CHEMBL2109527 ↗ |
| Modality | Monoclonal antibody | “MEDI-578, an Anti-NGF Monoclonal Antibody” NCT01072591 ↗ |
| Target | NGF | “Beta-nerve growth factor inhibitor” CHEMBL2109527 ↗ |